Literature DB >> 2252319

The hyperserotonemia of autism.

G M Anderson1, W C Horne, D Chatterjee, D J Cohen.   

Abstract

The planned and ongoing studies of platelet function and composition should allow us to better define the alteration which we presume to be present in platelets of autistic subjects. Although much of the research focuses on serotonergic aspects, the more general research should permit a better delineation of the extent of the alteration and will protect against a premature narrowing of the inquiry. The methodological development which has been a necessary aspect of the work should contribute to an improved understanding of platelet function and composition, as well as result in improved clinical tools for the assessment of platelet functioning in neuropsychiatric disorders and hematology. As an example, improvements in short-term in vitro storage conditions to stabilize aggregation and shape change responses over time were found to be necessary, and are probably critical to an optimal comparison of these phenomena across groups. The identification of the platelet alteration which is responsible for the hyperserotonemia of autism should prove useful in several ways. It would be expected that assessment of the altered function would provide a marker with less overlap with the normal population than the multidetermined measure of blood 5-HT. Determination of the specific protein(s) involved in the altered platelet should lead directly to gene probes and chromosomal location. These, in turn, should prove useful for neonatal screening, subtyping, and more powerful genetic and family studies. Work of this sort might also allow early intervention and improved treatment. Finally, characterization of the physiological alteration would provide a basis for focusing studies of brain neurochemistry and should, as well, suggest modes of neuropharmacological intervention. The confidence that one can have in the basic finding of hyperserotonemia in autism and the potential benefits to be derived from its explication make further research in this area of great interest.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2252319     DOI: 10.1111/j.1749-6632.1990.tb16893.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  45 in total

Review 1.  Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy.

Authors:  J K Buitelaar; S H Willemsen-Swinkels
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

Review 2.  Immune dysfunction in autism: a pathway to treatment.

Authors:  Milo Careaga; Judy Van de Water; Paul Ashwood
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

3.  Density and function of central serotonin (5-HT) transporters, 5-HT1A and 5-HT2A receptors, and effects of their targeting on BTBR T+tf/J mouse social behavior.

Authors:  Georgianna G Gould; Julie G Hensler; Teresa F Burke; Robert H Benno; Emmanuel S Onaivi; Lynette C Daws
Journal:  J Neurochem       Date:  2010-12-02       Impact factor: 5.372

4.  Acute dietary tryptophan manipulation differentially alters social behavior, brain serotonin and plasma corticosterone in three inbred mouse strains.

Authors:  Wynne Q Zhang; Corey M Smolik; Priscilla A Barba-Escobedo; Monica Gamez; Jesus J Sanchez; Martin A Javors; Lynette C Daws; Georgianna G Gould
Journal:  Neuropharmacology       Date:  2014-11-04       Impact factor: 5.250

5.  Whole Blood Serotonin Levels and Platelet 5-HT2A Binding in Autism Spectrum Disorder.

Authors:  Elizabeth Aaron; Alicia Montgomery; Xinguo Ren; Stephen Guter; George Anderson; Ana M D Carneiro; Suma Jacob; Matthew Mosconi; Ghanshyam N Pandey; Edwin Cook; Jeremy Veenstra-VanderWeele
Journal:  J Autism Dev Disord       Date:  2019-06

Review 6.  Ontogeny and regulation of the serotonin transporter: providing insights into human disorders.

Authors:  Lynette C Daws; Georgianna G Gould
Journal:  Pharmacol Ther       Date:  2011-04-05       Impact factor: 12.310

7.  The minicolumnopathy of autism: A link between migraine and gastrointestinal symptoms.

Authors:  Manuel F Casanova
Journal:  Med Hypotheses       Date:  2007-06-14       Impact factor: 1.538

Review 8.  Biomarkers in autism spectrum disorder: the old and the new.

Authors:  Barbara Ruggeri; Ugis Sarkans; Gunter Schumann; Antonio M Persico
Journal:  Psychopharmacology (Berl)       Date:  2013-10-06       Impact factor: 4.530

Review 9.  Exploring the multifactorial nature of autism through computational systems biology: calcium and the Rho GTPase RAC1 under the spotlight.

Authors:  Fares Zeidán-Chuliá; José Luiz Rybarczyk-Filho; Alla B Salmina; Ben-Hur Neves de Oliveira; Mami Noda; José Cláudio F Moreira
Journal:  Neuromolecular Med       Date:  2013-03-02       Impact factor: 3.843

10.  Plasma androgens in autism.

Authors:  S Tordjman; G M Anderson; P A McBride; M E Hertzig; M E Snow; L M Hall; P Ferrari; D J Cohen
Journal:  J Autism Dev Disord       Date:  1995-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.